Trading Activity and Price Movement
Lupin’s stock (symbol: LUPIN) opened at ₹2,360.0 on 10 Aug 2026, slightly below its previous close of ₹2,363.5, signalling a cautious start. The day’s trading saw a narrow price range, with the intraday high at ₹2,362.8 and a low of ₹2,235.0, reflecting a contraction in volatility. The last traded price (LTP) stood at ₹2,246.5 as of 13:24 IST, marking a day’s loss of 3.43%. This decline contributed to a cumulative fall of 6.49% over the last four consecutive trading days, indicating sustained selling pressure.
The weighted average price suggests that the bulk of the volume was traded closer to the day’s low, highlighting bearish sentiment among market participants. This is further corroborated by the stock opening with a gap down of 4.66%, a technical signal often interpreted as negative momentum.
Sector and Market Comparison
When benchmarked against its Pharmaceuticals & Biotechnology sector, Lupin underperformed by 4.31% on the day, while the Sensex managed a modest gain of 0.14%. The sector itself saw a marginal decline of 0.27%, underscoring Lupin’s relative weakness within its peer group. This divergence raises questions about the stock’s near-term outlook despite its mid-cap stature and ₹1,04,855 crore market capitalisation.
Institutional Interest and Liquidity
Institutional participation remains a critical factor in Lupin’s trading dynamics. Delivery volumes, a proxy for investor commitment, stood at 8.69 lakh shares on 7 Aug 2026 but have since declined by 3.94% against the five-day average delivery volume. This drop in investor participation could signal waning confidence or profit-booking by long-term holders.
Nevertheless, liquidity remains robust, with the stock’s traded value comfortably supporting trade sizes up to ₹7.5 crore based on 2% of the five-day average traded value. Such liquidity is favourable for institutional investors seeking to enter or exit sizeable positions without significant market impact.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Technical Indicators and Moving Averages
From a technical standpoint, Lupin’s price currently trades above its 200-day moving average, a long-term bullish indicator. However, it remains below its 5-day, 20-day, 50-day, and 100-day moving averages, signalling short- to medium-term weakness. This mixed technical picture suggests that while the stock retains some underlying strength, it is facing resistance and downward pressure in the near term.
The narrow intraday trading range of ₹1.6 on 10 Aug 2026, combined with the weighted average price skewed towards the lower end, indicates a consolidation phase with bearish undertones. Investors should monitor whether Lupin can reclaim its shorter-term moving averages to confirm a reversal or if the downtrend will persist.
Mojo Score and Rating Update
Lupin’s MarketsMOJO score currently stands at 74.0, reflecting a positive but cautious outlook. The stock’s mojo grade was downgraded from a Strong Buy to a Buy on 3 Aug 2026, signalling a moderation in conviction among analysts. This adjustment aligns with the recent price weakness and suggests that while Lupin remains a favourable investment within the Pharmaceuticals & Biotechnology sector, investors should be mindful of near-term risks.
The mid-cap classification further emphasises the stock’s growth potential balanced against volatility and liquidity considerations typical of this market segment.
Lupin Ltd. caught your attention? Explore our comprehensive research report with in-depth analysis of this mid-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth mid-cap analysis
- - Valuation assessment included
Outlook and Investor Considerations
Despite the recent price softness, Lupin’s strong market capitalisation and sector positioning continue to attract institutional interest. The stock’s liquidity profile supports active trading, which may appeal to both short-term traders and long-term investors seeking exposure to the Pharmaceuticals & Biotechnology space.
Investors should weigh the current technical weakness against Lupin’s fundamental strengths, including its mojo score and mid-cap growth potential. The downgrade from Strong Buy to Buy reflects a prudent reassessment rather than a fundamental deterioration, suggesting that the stock may offer attractive entry points on dips.
Monitoring delivery volumes and price action around key moving averages will be crucial in assessing whether Lupin can stabilise and resume an upward trajectory. Given the sector’s overall resilience and Lupin’s market stature, the stock remains a key watchlist candidate for investors seeking quality mid-cap pharmaceutical exposure.
Summary
Lupin Ltd. has emerged as one of the most actively traded stocks by value on 10 Aug 2026, with a total traded volume of 24,22,734 shares and a turnover exceeding ₹55,160 lakhs. However, the stock has underperformed its sector and the broader market, declining over 6.4% in the last four sessions. Institutional participation has slightly waned, and technical indicators point to short-term weakness despite a solid long-term base. The recent downgrade in mojo grade to Buy from Strong Buy signals a tempered but still positive outlook. Investors should remain vigilant for signs of recovery while appreciating the stock’s liquidity and mid-cap growth potential.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
